Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net Foundayo Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentHealth NetPolicy HNCA.CP.CPA.365

    Orforglipron (Foundayo) Coverage Criteria

    Customize your policy alerts

    Sign up for Health Net Policy HNCA.CP.CPA.365 alerts

    Get alerted when Policy HNCA.CP.CPA.365 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage criteria for Foundayo (orforglipron) for weight management in Health Net commercial and HIM members.

    Policy Summary
    PayerHealth Net
    PolicyOrforglipron (Foundayo) Coverage Criteria
    Policy CodePolicy HNCA.CP.CPA.365
    Change TypeNo material clinical or coverage change
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing the member meets BMI requirements and has participated in an approved weight-loss or lifestyle-modification program for at least 6 months before initial therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥6 monthsLifestyle program before treatment
    17.2 mg/dayMaximum covered dose
    16 weeksApproval duration
    >90 daysTherapy gap requiring new authorization
    ≥5%

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Weight loss for first renewal
    AdultsFDA-approved population

    Coverage Criteria

    Initial Therapy — Weight Management

    Covered for initial weight-management therapy when ALL applicable criteria below are met. The provider must submit office chart notes, laboratory results, or other clinical documentation supporting each criterion. Check the member's benefits because coverage and BMI requirements may vary by group and plan.

    ALL of the following

    • Member meets the applicable Body Mass Index requirement in Appendix B: generally BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related risk factor or obesity-related medical condition (such as coronary artery disease or heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference, or sleep apnea). Some large-group plans may require BMI ≥ 40 kg/m².

      Prior authorization may be required; verify the member's specific benefit and plan requirements.

    • Member is age ≥ 18 years.
    • Foundayo is not prescribed concurrently with another orforglipron-containing product or any other GLP-1 receptor agonist.
    • For a current member switching from Wegovy or Zepbound to Foundayo because of a weight-loss plateau, the BMI threshold initially used for approval may be used, provided there has been no gap in therapy of more than 90 days since the last refill date.

      A weight-loss plateau is cessation of weight loss before reaching the goal at approximately 6 to 9 months despite clinical interventions, including pharmacologic assistance.

    • Documentation supports participation in a Health Net-approved weight-loss program, such as Weight Watchers or Active&Fit, or another prescriber-recommended lifestyle modification plan that includes a reduced-calorie diet, increased physical activity, and behavioral modification.
    • Member has actively participated in the weight-loss program or lifestyle modification plan for at least 6 months before starting Foundayo.
    • Member agrees to remain actively enrolled in the weight-loss program or lifestyle modification plan throughout treatment with Foundayo.
    • Documentation includes the member's current height and body weight, obtained within the last 30 days, to calculate BMI.
    • Follow-up visits are planned to assess adherence and response to the treatment plan.
    • The requested dose does not exceed 17.2 mg once daily.

    Initial Therapy — Concurrent Type 2 Diabetes

    For members with concurrent type 2 diabetes mellitus, both requirements below must be met in addition to the initial weight-management criteria.

    ALL of the following

    • There has been failure of at least 3 consecutive months of treatment with each of the following: Ozempic or Rybelsus; Trulicity; liraglutide (generic Victoza); and Mounjaro.

      The requirement does not apply when clinically significant adverse effects are experienced or the therapies are contraindicated.

    • If the member is currently receiving a GLP-1 receptor agonist and is requesting a switch to Foundayo, medical justification supports the necessity of Foundayo.

      Intolerance due to common class adverse effects, such as gastrointestinal symptoms, is not acceptable medical justification.

    Continued Therapy — Weight Management

    Covered for continued weight-management therapy when ALL applicable criteria below are met.

    ALL of the following

    • ONE of the following

      • The member received compounded Foundayo, sample Foundayo, or Lily Direct® self-pay Foundayo; refer to the Initial Therapy criteria above.
      • The member is currently receiving the medication through a Centene benefit or has previously met the initial approval criteria.
      • The member is currently receiving the medication and is enrolled in a state and product subject to continuity-of-care regulations; refer to the applicable state-specific addenda for CC.PHARM.03A and CC.PHARM.03B.
    • ONE of the following response requirements

    Other Diagnoses and Indications

    For other diagnoses or indications, coverage follows the applicable pathway below.

    ONE of the following pathways

    • If the drug has undergone a label change within the last 6 months, such as a newly approved indication, age expansion, or new dosing regimen, that is not yet reflected in this policy, refer to CP.CPA.190 for the applicable commercial formulary or non-formulary pathway.
    • If the requested use, including diagnosis, age, or dosing regimen, is not specifically listed under Section III (Diagnoses/Indications for which coverage is NOT authorized), and the recent-label-change pathway does not apply, refer to the commercial off-label use policy CP.CPA.09.

    Check the member's benefits for coverage of weight-loss drugs; some large groups may have different BMI requirements and some PPO plans may not cover these drugs. Compounded medications and samples are excluded from coverage. Members receiving compounded, sample, or Lily Direct® self-pay Foundayo must be evaluated under the Initial Therapy criteria for continued requests.

    Coadministration of Foundayo with other orforglipron-containing products or any GLP-1 receptor agonist is not recommended and does not meet the policy's concurrent-use requirement.

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety under the off-label use policy CP.CPA.09 or applicable evidence-of-coverage documents.

    Eligibility and Effectiveness Thresholds

    WHO weight-status classification
    UnderweightBMI <18.5 kg/m²
    Normal rangeBMI 18.5–24.9 kg/m²
    OverweightBMI 25.0–29.9 kg/m²
    ObeseBMI ≥30 kg/m²
    Class I obesityBMI 30.0–34.9 kg/m²
    Class II obesityBMI 35.0–39.9 kg/m²
    Class III obesityBMI ≥40 kg/m²

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Initial Authorization

    Before initial authorization, submit documentation showing that the member meets the applicable BMI requirements, is at least 18 years old, has participated in an approved weight-loss program for at least 6 months, and agrees to continue the behavioral modification program throughout treatment. The request must also satisfy the applicable therapy, dosing, and follow-up requirements.

    • Participation must include a reduced-calorie diet, increased physical activity, and behavioral modification.
    • Initial approval duration is 16 weeks.
    Prior Authorization

    Continued Authorization

    For continued authorization, document that the member remains eligible for coverage, is responding positively to therapy, has current weight documentation, has planned follow-up, and remains actively enrolled in an approved weight-loss or prescriber-recommended lifestyle program. Continued approval duration is 16 weeks.

    • First renewal: document loss of at least 5% of baseline body weight.
    • Second and subsequent renewals: document weight loss and/or maintenance of weight loss on therapy.

    Therapy Overview

    Orforglipron (Foundayo) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist indicated for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term. The FDA-approved population includes adults with obesity and adults with overweight who have at least one weight-related comorbid condition. Continued behavioral and lifestyle modification is required alongside treatment.

    Definitions

    Weight-loss plateau
    DefinitionCessation of weight loss before reaching the member’s goal
    Approximate timingAround 6 to 9 months
    Despite interventionsOccurs despite clinical interventions, including pharmacologic assistance
    Body mass index
    BMIBody mass index
    CalculationBMI = 703 × [weight in pounds ÷ height in inches squared]
    Use in this policyBMI is used to classify weight status and evaluate weight-management eligibility

    Initial Therapy

    Initial Therapy Criteria

    Initial therapy is covered when all applicable criteria are met:

    Initial approval criteria

    • BMI requirement

      • Member has BMI ≥30 kg/m².
      • Member has BMI ≥27 kg/m² and at least one increased-risk indicator or other obesity-related medical condition, such as coronary artery or heart disease, hypertension, dyslipidemia, diabetes, elevated waist circumference, or sleep apnea.
      • The applicable benefit design requires and the member has BMI ≥40 kg/m².
    • Member is at least 18 years old.≥18 years

    Continued Therapy

    Continuation Therapy Criteria

    Continued therapy requires all applicable criteria:

    Continuation criteria

    • Approved continuation pathway

      • Member previously met initial approval criteria or is currently receiving Foundayo through the Centene benefit.
      • Member is currently receiving Foundayo and is enrolled in a state and product subject to continuity-of-care regulations.

        Refer to the applicable state-specific continuity-of-care addendum.

      • If the member received compounded, sample, or Lily Direct self-pay Foundayo, the member is evaluated under the initial-therapy criteria.
    • Required treatment response

    Prerequisite Medication Trials

    StepPrerequisite therapyRequired trial durationBefore Foundayo
    1Ozempic or RybelsusAt least 3 consecutive monthsFailure of therapy, unless clinically significant adverse effects occur or the therapy is contraindicated
    2TrulicityAt least 3 consecutive monthsFailure of therapy, unless clinically significant adverse effects occur or the therapy is contraindicated
    3Liraglutide (generic Victoza)At least 3 consecutive monthsFailure of therapy, unless clinically significant adverse effects occur or the therapy is contraindicated
    4MounjaroAt least 3 consecutive monthsFailure of therapy, unless clinically significant adverse effects occur or the therapy is contraindicated

    Dose Limits

    Foundayo (orforglipron) maximum covered dosage
    Maximum covered dose17.2 mg once daily
    Quantity limitFoundayo (orforglipron): 17.2 mg per day
    Coverage conditionRequests exceeding 17.2 mg once daily may be denied
    Policy Summary
    PayerHealth Net
    PolicyOrforglipron (Foundayo) Coverage Criteria
    Policy CodePolicy HNCA.CP.CPA.365
    Change TypeNo material clinical or coverage change
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing the member meets BMI requirements and has participated in an approved weight-loss or lifestyle-modification program for at least 6 months before initial therapy.
    SourceLink
    On This Page
    Coverage CriteriaEligibility and Effectiveness ThresholdsAuthorization, Documentation, and Denial RisksTherapy OverviewDefinitionsInitial TherapyContinued TherapyPrerequisite Medication TrialsDose Limits
    For the first renewal request, the member has lost at least 5% of baseline body weight.
  1. For a second or subsequent renewal request, the member has lost weight and/or maintained weight loss while on therapy.
  2. Documentation includes the member's current weight obtained within the last 30 days.
  3. Follow-up visits are planned to assess adherence and response to the treatment plan.
  4. Foundayo is not prescribed concurrently with another orforglipron-containing product or any other GLP-1 receptor agonist.
  5. Documentation shows that the member is actively enrolled in a Health Net-approved weight-loss program, such as Weight Watchers or Active&Fit, or a prescriber-recommended lifestyle modification plan that includes a reduced-calorie diet, increased physical activity, and behavioral modification as an adjunct to therapy.
  6. The requested dose does not exceed 17.2 mg once daily.
  7. Weight-management BMI eligibility
    Obesity thresholdBMI ≥30 kg/m²
    Overweight with riskBMI ≥27 kg/m² with at least one increased-risk indicator or other obesity-related medical condition, such as sleep apnea
    Certain benefit designsSome benefit designs may require BMI ≥40 kg/m²
    Weight-loss medication effectiveness
    Ineffectiveness threshold<5% weight loss after 3 months of therapy
    Clinical interpretationWeight loss below 5% after 3 months indicates that the weight-loss medication is ineffective
    Guideline actionThe medication should be discontinued and alternative medications considered
  8. Current weight must be documented within the last 30 days.
  9. Billing Rule

    Benefit Transition and Therapy Gaps

    Apply benefit-transition and therapy-gap rules when determining whether the member must satisfy the current plan’s BMI requirements.

    • Current Health Net members moving to a benefit plan with a higher BMI threshold are grandfathered and do not need to meet the higher threshold.
    • If the member stops taking the weight-loss drug for more than 90 days, calculated from the medication on hand since the last refill date, a new authorization is required under the current benefit, including a BMI of at least 40 when applicable.
    • Members newly transitioning to Health Net from another health plan are not grandfathered and must meet the applicable Health Net plan BMI requirements.
    Step Therapy

    Type 2 Diabetes Prerequisite Therapy

    For members with concurrent type 2 diabetes mellitus, document failure of the required sequential medication trials before requesting Foundayo, unless a medication caused clinically significant adverse effects or is contraindicated.

    • The member must generally fail at least 3 consecutive months of each applicable therapy: Ozempic or Rybelsus, Trulicity, liraglutide (generic Victoza), and Mounjaro.
    • Apply the exception when clinically significant adverse effects occur or a medication is contraindicated.
    Step Therapy

    Switching From Another GLP-1 or Obesity Drug

    When an existing member requests a switch from another GLP-1 receptor agonist or obesity drug, document the clinical rationale and applicable prior-approval history. Switching from Wegovy or Zepbound to Foundayo may use the BMI threshold initially used for approval if the switch is due to a weight-loss plateau and there has been no therapy gap exceeding 90 days since the last refill date.

    • A weight-loss plateau is cessation of weight loss before reaching the member’s goal at approximately 6 to 9 months despite clinical interventions, including pharmacologic assistance.
    • For a member currently receiving a GLP-1 receptor agonist, medical justification must support the need for Foundayo.
    • Intolerance to common GLP-1-class adverse effects, such as gastrointestinal symptoms, is not acceptable medical justification by itself.

    Unsupported block type: documentationный

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Contraindication

    Do not authorize Foundayo for a member with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2).

    • Foundayo is also contraindicated for known serious hypersensitivity to orforglipron or any Foundayo excipient.
    • The boxed warning addresses the risk of thyroid C-cell tumors.
    GLP-1
    GLP-1Glucagon-like peptide-1
    Drug classFoundayo is a GLP-1 receptor agonist
    Concurrent therapyFoundayo should not be prescribed with another GLP-1 receptor agonist
    MEN 2
    MEN 2Multiple endocrine neoplasia syndrome type 2
    Foundayo statusA personal or family history of MEN 2 is a contraindication to Foundayo
    Screening relevanceConfirm that the member does not have a personal or family history of MEN 2 before authorization
    MTC
    MTCMedullary thyroid carcinoma
    Foundayo statusA personal or family history of MTC is a contraindication to Foundayo
    Screening relevanceConfirm that the member does not have a personal or family history of MTC before authorization
    BMI calculation using pounds and inches
    FormulaBMI = 703 × [weight in pounds ÷ height in inches squared]
    Weight inputUse weight measured in pounds
    Height inputUse height measured in inches, squared in the denominator
    Coronary artery/heart disease
    Coronary artery bypass graftAn example of coronary artery or heart disease
    AnginaAn example of coronary artery or heart disease
    Myocardial infarctionA history of myocardial infarction is an example of coronary artery or heart disease
    StrokeA history of stroke is an example of coronary artery or heart disease
  10. Member has participated in an approved weight-loss program or prescriber-recommended lifestyle modification plan for at least 6 months before Foundayo and agrees to continue it throughout treatment.≥6 months before treatment

    The program must include a reduced-calorie diet, increased physical activity, and behavioral modification.

  11. Foundayo is not prescribed concurrently with another orforglipron-containing product or any other GLP-1 receptor agonist.
  12. If switching from Wegovy or Zepbound because of a weight-loss plateau, the BMI threshold initially used for approval may be used when there has been no therapy gap exceeding 90 days since the last refill.Therapy gap ≤90 days
  13. If switching from an existing GLP-1 receptor agonist, medical justification supports the necessity of Foundayo.

    Common gastrointestinal intolerance alone is not acceptable medical justification.

  14. If the member has concurrent type 2 diabetes mellitus, the additional diabetes therapy requirements are met.

    Failure of at least 3 consecutive months each of Ozempic or Rybelsus, Trulicity, liraglutide, and Mounjaro is required unless clinically significant adverse effects occur or the therapies are contraindicated.

  15. Current height and body weight are documented so BMI can be calculated, and follow-up visits are planned to assess adherence and response.Within the preceding 30 days
  16. The requested dose does not exceed 17.2 mg once daily.≤17.2 mg once daily
  17. For the first renewal, member has lost at least 5% of baseline body weight.≥5% of baseline body weight
  18. For a second or subsequent renewal, member has lost weight and/or maintained weight loss on therapy.
  19. Current body weight is documented.Within the preceding 30 days
  20. Follow-up visits are planned to assess adherence and response to the treatment plan.
  21. Member remains actively enrolled in a Health Net-approved weight-loss program or prescriber-recommended lifestyle modification plan involving a reduced-calorie diet, increased physical activity, and behavioral modification.
  22. Foundayo is not prescribed concurrently with another orforglipron-containing product or any other GLP-1 receptor agonist.
  23. The requested dose does not exceed 17.2 mg once daily.≤17.2 mg once daily